Pharmacotherapy of cognition in schizophrenia

Herbert Y Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Key issues in the pharmacotherapy of cognition in schizophrenia are whether atypical antipsychotic drugs (AAPDs) are effective to improve cognitive impairment in schizophrenia (CIS), possible biological bases for their efficacy, and the translational value of animal models. Although meta-analyses show modest beneficial effect of AAPDs for CIS, many consider them ineffective, mainly because of discounting improvements in subgroups of patients, overreliance on composite measures vs. specific domains as primary end points, reduced response in patients with tardive dyskinesia, and short clinical trials. AAPDs, and rarely typical APDs, ameliorate cognitive impairment in rodents following subchronic treatment with phencyclidine, an N-methyl-. d-aspartate receptor antagonist, possibly through enhancement of cortical and hippocampal dopaminergic, noradrenergic, cholinergic and glutamatergic neurotransmission, and diverse procognitive synaptic processes.

Original languageEnglish (US)
Pages (from-to)115-121
Number of pages7
JournalCurrent Opinion in Behavioral Sciences
Volume4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Cognition
Antipsychotic Agents
Schizophrenia
pamidronate
Drug Therapy
Phencyclidine
Synaptic Transmission
Cholinergic Agents
Meta-Analysis
Rodentia
Animal Models
Clinical Trials
Cognitive Dysfunction
Therapeutics
aspartic acid receptor
Tardive Dyskinesia

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Psychiatry and Mental health
  • Behavioral Neuroscience

Cite this

@article{2d5bf5892b264a32800511b8dc6034eb,
title = "Pharmacotherapy of cognition in schizophrenia",
abstract = "Key issues in the pharmacotherapy of cognition in schizophrenia are whether atypical antipsychotic drugs (AAPDs) are effective to improve cognitive impairment in schizophrenia (CIS), possible biological bases for their efficacy, and the translational value of animal models. Although meta-analyses show modest beneficial effect of AAPDs for CIS, many consider them ineffective, mainly because of discounting improvements in subgroups of patients, overreliance on composite measures vs. specific domains as primary end points, reduced response in patients with tardive dyskinesia, and short clinical trials. AAPDs, and rarely typical APDs, ameliorate cognitive impairment in rodents following subchronic treatment with phencyclidine, an N-methyl-. d-aspartate receptor antagonist, possibly through enhancement of cortical and hippocampal dopaminergic, noradrenergic, cholinergic and glutamatergic neurotransmission, and diverse procognitive synaptic processes.",
author = "Meltzer, {Herbert Y}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.cobeha.2015.04.009",
language = "English (US)",
volume = "4",
pages = "115--121",
journal = "Current Opinion in Behavioral Sciences",
issn = "2352-1546",
publisher = "Elsevier Limited",

}

Pharmacotherapy of cognition in schizophrenia. / Meltzer, Herbert Y.

In: Current Opinion in Behavioral Sciences, Vol. 4, 01.08.2015, p. 115-121.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacotherapy of cognition in schizophrenia

AU - Meltzer, Herbert Y

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Key issues in the pharmacotherapy of cognition in schizophrenia are whether atypical antipsychotic drugs (AAPDs) are effective to improve cognitive impairment in schizophrenia (CIS), possible biological bases for their efficacy, and the translational value of animal models. Although meta-analyses show modest beneficial effect of AAPDs for CIS, many consider them ineffective, mainly because of discounting improvements in subgroups of patients, overreliance on composite measures vs. specific domains as primary end points, reduced response in patients with tardive dyskinesia, and short clinical trials. AAPDs, and rarely typical APDs, ameliorate cognitive impairment in rodents following subchronic treatment with phencyclidine, an N-methyl-. d-aspartate receptor antagonist, possibly through enhancement of cortical and hippocampal dopaminergic, noradrenergic, cholinergic and glutamatergic neurotransmission, and diverse procognitive synaptic processes.

AB - Key issues in the pharmacotherapy of cognition in schizophrenia are whether atypical antipsychotic drugs (AAPDs) are effective to improve cognitive impairment in schizophrenia (CIS), possible biological bases for their efficacy, and the translational value of animal models. Although meta-analyses show modest beneficial effect of AAPDs for CIS, many consider them ineffective, mainly because of discounting improvements in subgroups of patients, overreliance on composite measures vs. specific domains as primary end points, reduced response in patients with tardive dyskinesia, and short clinical trials. AAPDs, and rarely typical APDs, ameliorate cognitive impairment in rodents following subchronic treatment with phencyclidine, an N-methyl-. d-aspartate receptor antagonist, possibly through enhancement of cortical and hippocampal dopaminergic, noradrenergic, cholinergic and glutamatergic neurotransmission, and diverse procognitive synaptic processes.

UR - http://www.scopus.com/inward/record.url?scp=84935851811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935851811&partnerID=8YFLogxK

U2 - 10.1016/j.cobeha.2015.04.009

DO - 10.1016/j.cobeha.2015.04.009

M3 - Review article

AN - SCOPUS:84935851811

VL - 4

SP - 115

EP - 121

JO - Current Opinion in Behavioral Sciences

JF - Current Opinion in Behavioral Sciences

SN - 2352-1546

ER -